Exelixis Settles With Cipla To Resolve Two Patent Litigation; Grants Cipla License To Market Generic Versions Of CABOMETYX On Jan 1, 2031 If Approved By FDA And Subject To Conditions; Parties Terminate All Hatch-Waxman Litigation Regarding CABOMETYX
Portfolio Pulse from Benzinga Newsdesk
Exelixis has settled its patent litigation with Cipla, granting Cipla a license to market generic versions of CABOMETYX starting January 1, 2031, pending FDA approval and other conditions. All Hatch-Waxman litigation regarding CABOMETYX has been terminated.
May 20, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exelixis has resolved its patent litigation with Cipla, allowing Cipla to market generic versions of CABOMETYX starting January 1, 2031, if approved by the FDA. This settlement terminates all Hatch-Waxman litigation regarding CABOMETYX.
The settlement removes legal uncertainties and potential costs associated with ongoing litigation, which is positive for Exelixis. However, the introduction of a generic version in 2031 could impact long-term revenue from CABOMETYX.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100